Evidence map›Paper›PMID 34644563›Full record

ArticleCell reports2021

PI3Kδ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8

Jennifer L Cannons, Alejandro V Villarino, Senta M Kapnick, Silvia Preite, Han-Yu Shih, Julio Gomez-Rodriguez, Zenia Kaul, Hirofumi Shibata, Julie M Reilley, Bonnie Huang and 10 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Activated PIK3CD drives marginal zone B cell development from early transitional progenitors by enhancing ADAM10 expression.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Engineering metabolism to modulate immunity.Advanced drug delivery reviews · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Cutting Edge: Promoting T Cell Factor 1Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Jennifer L CannonsNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA. Electronic address: jcannons@mail.nih.gov.
Alejandro V VillarinoNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892, USA; Department of Microbiology & Immunology and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
Senta M KapnickNational Human Genome Research Institute, NIH, Bethesda, MD 20892, USA; Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
Silvia PreiteNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
Han-Yu ShihNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892, USA; National Eye Institute, NIH, Bethesda, MD 20892, USA.
Julio Gomez-RodriguezNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA; TCR2 Therapeutics, Cambridge, MA 02142, USA.
Zenia KaulNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Hirofumi ShibataNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Julie M ReilleyNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
Bonnie HuangNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
Robin HandonNational Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
Ian T McBainNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Selamawit GossaNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
Tuoqi WuNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA; University of Colorado, Department of Immunology, Denver, CO 80204, USA; Department of Immunology and Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390.
Helen C SuNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Dorian B McGavernNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
John J O'SheaNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892, USA.
Peter J McGuireNational Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.
Gulbu UzelNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Pamela L SchwartzbergNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA. Electronic address: pams@nih.gov.
National Human Genome Research Institute · USNational Institute of Allergy and Infectious Diseases · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institute of Neurological Disorders and Stroke · USUniversity of Miami · US

Funding

Genetic and Biochemical Approaches to Tyrosine Kinase and Lymphocyte SignalingZIAAI001240 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SCHWARTZBERG, PAMELA · 2019 to 2025
$18.8M
Intramural NIH HHS ZIA AI001240
6 · The paper itself

Abstract

Patients with activated phosphatidylinositol 3-kinase delta (PI3Kδ) syndrome (APDS) present with sinopulmonary infections, lymphadenopathy, and cytomegalvirus (CMV) and/or Epstein-Barr virus (EBV) viremia, yet why patients fail to clear certain chronic viral infections remains incompletely understood. Using patient samples and a mouse model (Pik3cd

Indexed as

Chromatin Assembly and DisassemblyImmunologic MemoryTranscription, GeneticAdolescentAdultAnimalsApoptosisCase-Control StudiesCD8-Positive T-LymphocytesChildChromatinClass I Phosphatidylinositol 3-KinasesDisease Models, AnimalEnzyme ActivationFas Ligand ProteinFemaleChromatinClass I Phosphatidylinositol 3-KinasesFASLG protein, humanFas Ligand ProteinFasl protein, mousePIK3CD protein, humanPik3cd protein, mouseapoptosisCD8 T cell memoryeffector T cellsIL-2long-lived effector cells (LLEC)metabolismmTORMycPhosphatidylinositide 3 Kinase delta (PI3Kδ)TCF1

Identifiers

PMID34644563
PMCPMC8582080
OpenAlexW3207059701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.